Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 13/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | CASP3 | P42574 | 3/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.72 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.68 |
| ▸ | TUBB | P07437 | 2/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533833 | 1.00 | RAB9A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL5776766 | 0.84 | RAB9A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL5776769 | 0.84 | RAB9A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL16383880 | 0.84 | RAB9A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL17712436 | 0.84 | RAB9A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL1508835 | 0.81 | TUBB4A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL1508832 | 0.81 | TUBB4A (1.00) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL12066528 | 0.80 | TUBB4A (0.74) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL12066518 | 0.80 | TUBB4A (0.74) | RAB9AKDM4ELMNANPC1POLB | |
| SCHEMBL13779284 | 0.79 | ABL1 (0.80) | RAB9AKDM4ELMNANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | RAB9A 1048/4885KDM4E 3578/4885LMNA 2412/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | RAB9A 1097/4885KDM4E 3491/4885LMNA 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.